Tafenoquine

60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world’s first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients. The FDA has granted its investigational tafenoquine candidate orphan drug designation for the treatment of patients with acute babesiosis.
Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA and in Australia as KODATEF. It is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older.